Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Cancer Res. 2009 Nov 10;69(23):9012–9019. doi: 10.1158/0008-5472.CAN-09-2019

Figure 3. Therapeutic anti-tumor effects of Trp2180–188-TriVax.

Figure 3

(A), B6 mice (4 per group) received 3 × 105 B16Fl0 cells i.v., and 3 and 11 days later the mice were vaccinated with Trp2180–188-TriVax or Ova55–63-TriVax. A non-vaccinated group (No Vax) was also included. On Day 24 (when the control mice appeared sick), the presence of B16 pulmonary nodules was evaluated. Results are presented as “Numbers of Lung Tumors” and “Lung Weights” for individual mice. Representative photographs of lungs of 2 mice from each group are shown. Splenocytes from mice of the 2 vaccinated groups in “A” were evaluated for Trp2-specific CD8 T cells by tetramer analysis (B), and antigen-induced IFNγ production in EliSpot assays (C). P values were calculated using unpaired Student’s test.